Phase IIb Study of AST-3424 in Patients With AKR1C3-high Expressing Advanced Hepatocellular Carcinoma

计划入组 75 人 · 首次发布于 2025 年 12 月 30 日

Study to Test OBI-3424 in Patients With T-Cell Acute Lymphoblastic Leukemia (T-ALL) or T-Cell Lymphoblastic Lymphoma (T-LBL)

计划入组 67 人 · 首次发布于 2020 年 3 月 19 日

A Phase I/II Study of AST-001 in Subjects With Advanced Solid Tumors

计划入组 180 人 · 首次发布于 2024 年 2 月 7 日

AKR1C3 inhibitors (cancer)

AKR1C3 inhibitor(University of Pennsylvania)

AKR1C3 inhibitor(Queen Elizabeth Hospital)

ARC3 GASES, INC.

United States

OBI Pharma's Novel TROP2 ADC OBI-902 Receives FDA IND Clearance for Phase 1/2 Trial Using Proprietary GlycOBI® Technology

OBI Pharma and TegMine Therapeutics Form Global License Partnership for Novel Glycan-Targeting ADC